Topiramate reduces ethanol consumption by C57BL/6 mice

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• Topiramate (TPM) may treat alcohol dependence by reducing alcohol's rewarding effects.
• TPM's mechanism may involve inhibiting dopamine release and antagonizing alcohol-induced changes at AMPA and kainate receptors.

Purpose of the Study:

• To evaluate the effect of topiramate (TPM) on alcohol consumption in a C57BL/6 (B6) murine model.
• To assess dose-dependency and potential adverse effects of TPM on alcohol intake.

Main Methods:

• B6 mice (n=40) received subcutaneous injections of TPM (0, 10, 30, 90 mg/kg) 60 minutes before access to 12% ethanol solution.
• Alcohol consumption was measured over a 21-hour period for 8 consecutive days.

Main Results:

• TPM administration resulted in a dose-responsive reduction in alcohol consumption during the initial 2-hour period post-injection.
• Ethanol intake (g/kg) decreased across treatment groups (SAL, T10, T30, T90) from 1.34 to 0.67.
• No significant effects on food consumption, body weight, or motor activity were observed at tested TPM doses.

Conclusions:

• Mice did not develop tolerance to TPM-induced reductions in ethanol intake, unlike with naltrexone or tiagabine.
• TPM effectively reduced ethanol intake in the B6 mouse model at doses without apparent adverse effects.
• Further research is warranted to characterize TPM as a potential therapeutic agent for alcohol dependence.